Gastric Antisecretory Drug Market Report 2026

Gastric Antisecretory Drug Market Overview

• Gastric Antisecretory Drug market size has reached to $15.63 billion in 2025 • Expected to grow to $20.7 billion in 2030 at a compound annual growth rate (CAGR) of 5.8% • Growth Driver: Rise In Gastrointestinal Disorders Fueling The Growth Of The Market Due To Increasing Acid-Related Complications • Market Trend: Development Of Advanced Antisecretory Formulations Offering Enhanced And Sustained Gastrointestinal Relief • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gastric Antisecretory Drug Market?

A gastric antisecretory drug is a type of medication designed to reduce gastric acid production in the stomach. These drugs work by inhibiting specific pathways or receptors in stimulating acid secretion, thereby decreasing the overall acidity of the stomach contents. A gastric antisecretory drug helps maintain a more neutral pH in the gastric environment, which can be beneficial for protecting the stomach lining and supporting digestive balance. The main drug classes of gastric antisecretory drugs include proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, and prostaglandin analogs. Proton pump inhibitors (PPIs) are a class of medications that reduce stomach acid production by irreversibly blocking the enzyme H⁺/K⁺-ATPase in the gastric parietal cells. It can be administered through various routes such as oral, intravenous, and topical and is distributed through several channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. It is applied for gastroesophageal reflux disease, peptic ulcer disease, Zollinger-Ellison syndrome, and others.

What Is The Gastric Antisecretory Drug Market Growth Forecast?

The gastric antisecretory drug market size is expected to see strong growth in the next few years. It will grow to $20.7 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to aging population growth, rising stress-related gastric disorders, expansion of otc drug markets, increased healthcare awareness, development of safer long-term therapies. Major trends in the forecast period include increasing use of proton pump inhibitors, rising demand for long-term acid suppression, growing preference for oral drug formulations, expansion of over-the-counter availability, increasing focus on gastrointestinal disease management.

Global Gastric Antisecretory Drug Market Segmentation

1) By Drug Class: Proton Pump Inhibitors (PPIs), H2 Receptor Antagonists, Antacids, Prostaglandin Analogs 2) By Route Of Administration: Oral, Intravenous 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels 4) By Application: Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Zollinger-Ellison Syndrome, Other Applications Subsegments: 1) By Proton Pump Inhibitors (PPIs): Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole, Dexlansoprazole 2) By H2 Receptor Antagonists: Ranitidine, Famotidine, Cimetidine, Nizatidine 3) By Antacids: Magnesium Hydroxide, Calcium Carbonate, Aluminum Hydroxide, Sodium Bicarbonate, Combination Antacids 4) By Prostaglandin Analogs: Misoprostol, Enprostil

What Is The Driver Of The Gastric Antisecretory Drug Market?

The prevalence of gastrointestinal disorders is anticipated to propel the growth of the gastric antisecretory drug market in the coming years. Gastrointestinal disorders affect the digestive tract, including the stomach, intestines, and associated organs, leading to symptoms such as pain, bloating, and altered bowel movements. The rise in gastrointestinal disorders is primarily driven by poor dietary habits, with excessive intake of processed foods and insufficient fiber leading to imbalances in gut microbiota and impaired digestion. Gastric antisecretory drugs are required, as excessive stomach acid can damage the protective lining of the gastrointestinal tract, leading to irritation or injury that these drugs help prevent by reducing acid production. For instance, inJune 2025, according to the Turkish Journal Of Gastroenterology, a Turkey-based journal, 6.9 million individuals globally suffering from inflammatory bowel disease (IBD) currently. Therefore, the increasing prevalence of gastrointestinal disorders will boost the growth of the gastric antisecretory drug industry.

Key Players In The Global Gastric Antisecretory Drug Market

Major companies operating in the gastric antisecretory drug market are Pfizer Inc., Bayer AG, AstraZeneca plc, Takeda Pharmaceutical Company Ltd., Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Chemo Biological, Spansules Pharmatech Pvt. Ltd., Phoenix Biologicals Pvt. Ltd., Centurion Remedies Private Limited, Solitaire Pharmacia Pvt. Ltd., Shreeji Pharma International, Estrellas Life Sciences Private Limited, 3s Corporation, Actiza Pharmaceutical Private Limited, Lark Laboratories, Cytonova Labs International Private Limited, Luckys Pharma Lab Pvt. Ltd., Lexicare Pharma Pvt. Ltd., Mustcure Healthcare LLP

Global Gastric Antisecretory Drug Market Trends and Insights

Major companies operating in the gastric antisecretory drug market are focusing on developing advanced products, such as antisecretory compounds, to provide longer-lasting relief. Antisecretory compounds are substances that reduce or inhibit the secretion of bodily fluids, particularly gastric acid, by acting on specific cellular pathways or receptors. For instance, in June 2024, Akums Drugs and Pharmaceuticals, an India-based pharmaceutical company, launched Rabeprazole + Levosulpiride SR Capsules, a new formulation for Gastrointestinal patients. This formulation uniquely combines rabeprazole sodium, a potent antisecretory agent that selectively inhibits the H⁺/K⁺ ATPase in gastric parietal cells, with levosulpiride, known for its central antidopaminergic and antiemetic properties. The capsule delivers 40 mg of enteric-coated rabeprazole and 75 mg of sustained-release levosulpiride, ensuring targeted and prolonged therapeutic action. Its dual mechanism addresses both acid suppression and gastrointestinal motility regulation.

What Are Latest Mergers And Acquisitions In The Gastric Antisecretory Drug Market?

In July 2024, Merit Medical Systems, Inc., a US-based developer and manufacturer of disposable medical devices for interventional and diagnostic procedures, acquired the EsophyX Z+ device and related assets from EndoGastric Solutions, Inc. for ~$105 million. With this acquisition, Merit aims to strengthen its gastrointestinal / endoscopy portfolio by adding a durable, minimally invasive, non-pharmacological treatment for GERD, thereby complementing drug-based acid suppression therapies. EndoGastric Solutions, Inc. is a U.S.-based company that develops the EsophyX Z+ system for transoral incisionless fundoplication.

Regional Insights

North America was the largest region in the gastric antisecretory drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gastric Antisecretory Drug Market?

The gastric antisecretory drug market consists of sales of mucosal protective agents, digestive enzyme supplements, probiotics for gut health, and controlled-release formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gastric Antisecretory Drug Market Report 2026?

The gastric antisecretory drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gastric antisecretory drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.